-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on NeoGenomics, Raises Price Target to $14

Benzinga·08/29/2025 18:27:44
Listen to the news
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $8 to $14.